Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for IN8bio, Inc. (INAB : NSDQ)
 
 • Company Description   
IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York.

Number of Employees: 19

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.58 Daily Weekly Monthly
20 Day Moving Average: 20,350 shares
Shares Outstanding: 18.84 (millions)
Market Capitalization: $48.60 (millions)
Beta:
52 Week High: $10.32
52 Week Low: $2.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.34% -14.78%
12 Week -41.76% -35.97%
Year To Date -41.23% -28.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
350 5th Avenue Suite 5330
-
New York,NY 10118
USA
ph: 646-600-6438
fax: -
dbuck@soleburytrout.com http://www.in8bio.com
 
 • General Corporate Information   
Officers
William Ho - Chief Executive Officer and Director
Alan S. Roemer - Chairman
Patrick McCall - Chief Financial Officer and Secretary
Peter Brandt - Director
Emily Fairbairn - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45674E109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/09/22
Share - Related Items
Shares Outstanding: 18.84
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $48.60 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.38 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.48
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -57.14%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -82.53
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -53.40
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - 16.09
12/31/21 - 17.28
09/30/21 - 20.31
Quick Ratio
03/31/22 - -
12/31/21 - 17.28
09/30/21 - 20.31
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.74
12/31/21 - 2.04
09/30/21 - 2.29
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.01
12/31/21 - 0.01
09/30/21 - 0.01
Debt-to-Capital
03/31/22 - 0.61
12/31/21 - 0.70
09/30/21 - 0.79
 

Powered by Zacks Investment Research ©